Clonidine is Better Than Zopiclone for Insomnia Treatment in Chronic Pain Patients

Sponsor
Salem Anaesthesia Pain Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT05277038
Collaborator
(none)
150
1
30
152.2

Study Details

Study Description

Brief Summary

A prospective observational crossover study of 160 consenting adult patients who underwent pain management. For insomnia treatment, each patient ingested different prescribed doses of Zopiclone or Clonidine on alternate nights. Each patient used a special validated sleep diary to collect data including pain score, sleep scores, sleep duration, sleep medication dose, and adverse effects. Each patient completed the diary for 3 continuous weeks. Pain was measured using the numeric pain rating scale. Sleep score was measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points was considered significant.

Condition or Disease Intervention/Treatment Phase
  • Drug: Clonidine pill

Detailed Description

Objectives: Chronic pain is associated with insomnia. The objective of this clinical study is to compare the efficacy and safety of different prescribed doses of Zopiclone and Clonidine; for the management of insomnia in patients with chronic pain.

Methods: A prospective observational crossover study of 160 consenting adult patients who underwent pain management. For insomnia treatment, each patient ingested different prescribed doses of Zopiclone or Clonidine on alternate nights. Each patient used a special validated sleep diary to collect data including pain score, sleep scores, sleep duration, sleep medication dose, and adverse effects. Each patient completed the diary for 3 continuous weeks. Pain was measured using the numeric pain rating scale. Sleep score was measured using the Likert sleep scale. A change in the pain or sleep scores by 2-points was considered significant. Data were analyzed with IBM® SPSS® Statistics 25 (IBM Corp, Armonk, NY); using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value <0.05 was considered significant.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
150 participants
Observational Model:
Case-Crossover
Time Perspective:
Prospective
Official Title:
Clonidine is Better Than Zopiclone for Insomnia Treatment in Chronic Pain Patients
Actual Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Mar 31, 2022
Anticipated Study Completion Date :
Mar 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Clonidine vs Zopiclone for insomnia

Consecutive adult patients who underwent pain management at a Canadian pain clinic. The patients were subsequently prescribed and provided zopiclone 3.75mg tablet (1-2 tablets per dose), and clonidine 0.1mg tablet (1-2 tablets per dose). They were advised to take either clonidine or zopiclone on alternate nights. For each medication, they alternated the doses of 1 tablet or 2 tablets at subsequent nightly administrations. The four possible medication doses were zopiclone 3.75mg, zopiclone 7.5mg, clonidine 0.1mg, and clonidine 0.2mg; as shown on the sleep diary in Figure 1. The recommended orders of treatment were zopiclone 7.5mg, clonidine 0.1mg, zopiclone 3.75mg, clonidine 0.2mg; or clonidine 0.2mg, zopiclone 3.75mg, clonidine 0.1mg, zopiclone 7.5mg. Each patient participated in the study treatment and completed the sleep diary for 3 continuous weeks. Therefore, each of the four medication doses was used five times by each patient.

Drug: Clonidine pill
Routine prescription for insomnia
Other Names:
  • Zopiclone pill
  • Outcome Measures

    Primary Outcome Measures

    1. Sleep quality [3 weeks]

      Sleep quality score, objective measurement using the validated Likert sleep scale tool.

    Secondary Outcome Measures

    1. Analgesia [3 weeks]

      Pain score, objective measurement using the validated Numeric Pain Rating scale tool.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • adult chronic pain patients

    • good treatment compliance

    • severe chronic insomnia

    • failure of non-pharmacologic sleep therapy

    • regular zopiclone therapy for 3 months or more

    • regular sleep diary

    • regular pain diary

    • informed consent for diary review

    • consent for clinical record quality assurance review.

    Exclusion Criteria:
    • obstructive sleep apnoea

    • body mass index (BMI) ≥40

    • organ insufficiency

    • cognitive disorder

    • inability to provide consent

    • major neuropsychiatric disorder

    • unreliable diary

    • cannabis use

    • regular alcohol intake

    • stimulant use

    • substance abuse

    • poor treatment compliance

    • high dose opioid

    • gabapentinoid use

    • sedative use

    • mild insomina

    • irregular zopiclone intake

    • regular zopiclone therapy for less than 3 months

    • previous adverse/allergic reactions to clonidine or zopiclone.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Salem Anaesthesia Clinic Surrey British Columbia Canada V4P 1G1

    Sponsors and Collaborators

    • Salem Anaesthesia Pain Clinic

    Investigators

    • Principal Investigator: Olu Bamgbade, Salem Anaesthesia Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Salem Anaesthesia Pain Clinic
    ClinicalTrials.gov Identifier:
    NCT05277038
    Other Study ID Numbers:
    • SalemAnaesth 2021 ClonZop
    First Posted:
    Mar 14, 2022
    Last Update Posted:
    Mar 14, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Salem Anaesthesia Pain Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 14, 2022